Joe C. Pillman

Retired Partner

Joe Pillman is a retired partner who built a substantial practice working with local, national and international companies on a variety of corporate matters. His practice concentrated on venture capital, corporate finance, mergers and acquisitions and international law. With his extensive experience and knowledge of a wide range of transactions, Mr. Pillman successfully represented a variety of clients, and had a particular reputation for representing those in the life sciences and technology sectors.

Mr. Pillman focused on securities law, including public and private securities offerings, mergers and acquisitions, as well as a range of international matters, including public and private placements for overseas issuers, and inward and outward bound acquisition transactions. He also has extensive experience with management and leveraged buy-outs, venture capital transactions and other private fund raising issues.

Mr. Pillman's clients included companies engaged in a wide range of technology sectors such as life sciences, telecommunications equipment, networking systems, Internet infrastructure, semiconductor design and manufacture, and advanced software systems and applications products.


Recent Highlights

  • MBO of PowderMed from Chiron
  • Sale of Domantis to GSK
  • Sale of Avidex to MediGene


  • Regularly named as a leading corporate practitioner in Chambers Guide to the Legal Profession.
  • Recommended in the 2008–2014 editions of The Legal 500 UK for venture capital and mergers and acquisitions: mid market, with sources stating that he is "superb," "very responsive" and "well regarded for [his] advice."

Insights & News


  • Education

    • MA, University of Cambridge

  • Admissions

    • England and Wales, Solicitor



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.